The Future of Market Access

$695
Maximum Purchase:
1 unit
Publication Date:
August 2016
Format:
PDF
Adding to cart… The item has been added

What does the future hold for Market Access?  

The profile of Market Access (MA) departments is on the up.  No longer simply existing as a ‘bolt on’ for other, more traditional activities, MA is pushing back the marketing boundaries. How is this multi-disciplined area evolving? And what must pharma companies do to stay ahead?  FirstWord Dossier: The Future of Market Access examines the challenges and issues that are shaping markets and impacting the bottom line.

In this new report, 8 leading market access specialists from European and US pharmaceutical companies and consultancies share their expert insight. Find out what the future holds and how best to navigate this fast-moving landscape.

“The companies that succeed will be the ones that have nimble and dynamic structures and value propositions which are capable of evolving as market access environments progress. The players in the field [sales representatives, medical science liaisons, market access, NHS system change experts, data experts, economists] are unlikely to change but the mix needed certainly will.”
Paul Catchpole, Value and Access Director, ABPI

Report available for immediate download - place your order today

Top Takeaways and Key Questions

  • Cost is not the only factor driving decisions: Yes, payers are actively looking for ways to keep control of rising costs – but what else is significantly influencing market uptake?
  • Pharma isn’t yet meeting real world evidence needs adequately: What improvements can be made in data gathering? Are the right questions being answered (or asked)? What is the single, biggest issue?
  • Multi-disciplinary strategies are a must to overcome the ‘fourth hurdle’: How best to engage with multiple stakeholders and meet the challenges posed by healthcare reform and austerity?
  • Holistic, integrated approach vs defined specialisms: When should MA planning begin? How much common ground is there? What elements do successful MA approaches share?
  • What next for HTAs?: Can (and should) Health Technology Assessment requirements be harmonised? If so, who benefits?

Find answers to these and many more important questions — download the report today

Experts Interviewed for This Report

  • Colin Wight, Chief Executive and Founder, GalbraithWight Ltd
  • Janice Haigh, Principal, Quintiles Advisory Services, Europe
  • Paul Catchpole, Value and Access Director, Association of the British Pharmaceutical Industry
  • Sean McGrath, Chairman and Founding Partner, Succinct Medical Communications Group and Director of Oncology, the OPEN Health Group
  • Steve Turley, Managing Director, UCB
  • Market Access Expert, European Pharma Company
  • Market Access Expert, European Specialist Pharma Company
  • Market Access Expert, US Pharma Company

Need more information? Contact a consultant for an executive summary and sample pages from the report.

Get this report now

What does the future hold for Market Access?  

The profile of Market Access (MA) departments is on the up.  No longer simply existing as a ‘bolt on’ for other, more traditional activities, MA is pushing back the marketing boundaries. How is this multi-disciplined area evolving? And what must pharma companies do to stay ahead?  FirstWord Dossier: The Future of Market Access examines the challenges and issues that are shaping markets and impacting the bottom line.

In this new report, 8 leading market access specialists from European and US pharmaceutical companies and consultancies share their expert insight. Find out what the future holds and how best to navigate this fast-moving landscape.

“The companies that succeed will be the ones that have nimble and dynamic structures and value propositions which are capable of evolving as market access environments progress. The players in the field [sales representatives, medical science liaisons, market access, NHS system change experts, data experts, economists] are unlikely to change but the mix needed certainly will.”
Paul Catchpole, Value and Access Director, ABPI

Report available for immediate download - place your order today

Top Takeaways and Key Questions

  • Cost is not the only factor driving decisions: Yes, payers are actively looking for ways to keep control of rising costs – but what else is significantly influencing market uptake?
  • Pharma isn’t yet meeting real world evidence needs adequately: What improvements can be made in data gathering? Are the right questions being answered (or asked)? What is the single, biggest issue?
  • Multi-disciplinary strategies are a must to overcome the ‘fourth hurdle’: How best to engage with multiple stakeholders and meet the challenges posed by healthcare reform and austerity?
  • Holistic, integrated approach vs defined specialisms: When should MA planning begin? How much common ground is there? What elements do successful MA approaches share?
  • What next for HTAs?: Can (and should) Health Technology Assessment requirements be harmonised? If so, who benefits?

Find answers to these and many more important questions — download the report today

Experts Interviewed for This Report

  • Colin Wight, Chief Executive and Founder, GalbraithWight Ltd
  • Janice Haigh, Principal, Quintiles Advisory Services, Europe
  • Paul Catchpole, Value and Access Director, Association of the British Pharmaceutical Industry
  • Sean McGrath, Chairman and Founding Partner, Succinct Medical Communications Group and Director of Oncology, the OPEN Health Group
  • Steve Turley, Managing Director, UCB
  • Market Access Expert, European Pharma Company
  • Market Access Expert, European Specialist Pharma Company
  • Market Access Expert, US Pharma Company

Get this report now